Onassis Holdings Launches $75 Million Regulation A+ Financing Round for Biotech Longevity Research

Onassis Holdings (OTC: ONSS), a biotechnology holding company specializing in longevity and rejuvenation technologies, has announced the launch of a Regulation A+ financing round through an agreement with Dalmore Group. This financing initiative enables the company to raise up to $75 million annually from public investors, marking a significant step in funding its epigenetic reprogramming research.

The partnership with Dalmore Group brings substantial expertise to the financing effort, as the firm has onboarded more than 270 Regulation A+ issuers since 2021 and possesses over 16 years of experience in the field. Dalmore provides comprehensive support services including marketing and public relations assistance, marketplace syndication, and secondary trading solutions for issuers participating in Regulation A+ offerings.

Onassis Holdings focuses on epigenetic reprogramming technologies aimed at rejuvenating elderly cells while maintaining their distinct biological properties. The company's subsidiary, Ananda Labs, is developing groundbreaking therapies based on patented proteins designed to reverse cellular aging processes. This research represents a growing segment within the biotechnology industry focused on addressing age-related diseases and extending human healthspan.

The Regulation A+ financing structure allows smaller companies to raise capital from both accredited and non-accredited investors through public offerings, providing greater accessibility to investment opportunities in emerging biotechnology firms. This approach has gained popularity as an alternative to traditional funding methods, particularly for companies operating in innovative but capital-intensive research areas like longevity science.

The announcement was disseminated through InvestorWire, a specialized communications platform that provides wire-grade press release syndication services for public and private companies. The platform offers access to extensive distribution networks, article syndication to more than 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers through its parent company's brand portfolio.

This financing round comes at a time when investor interest in longevity and rejuvenation biotechnology is growing significantly. The field has attracted attention from both institutional and retail investors seeking exposure to innovative approaches addressing age-related health challenges. The successful execution of this Regulation A+ offering could provide Onassis Holdings with the necessary capital to advance its research programs and potentially bring novel therapeutic approaches closer to clinical application.

The company maintains additional information about its operations and research focus available through its corporate website at https://www.onassis-holdings.com/. The full details of the financing announcement can be accessed through the original press release available at https://ibn.fm/s9HOQ.